Regulation of Osteoclast Differentiation by Cytokine Networks

키워드

참고문헌 (127)

1. 노재랑, "Osteoimmunology: Interactions of the Immune and Skeletal Systems", Molecules and Cells, 17(1), pp.1~9 (2004), 한국분자세포생물학회
2. Takayanagi H, "Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems", Nat Rev Immunol, 7, pp.292~304 (2007)[DOI]
3. Walsh MC, "Osteoimmunology: interplay between the immune system and bone metabolism", Annu Rev Immunol, 24, pp.33~63 (2006)[DOI]
4. -related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor, "J Exp Med", 1997, 2075~2080, 10.1084[DOI]
5. Bucay N, "osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification", Genes Dev, 12, pp.1260~1268 (1998)[DOI]
6. Amarasekara DS, "Bone loss triggered by the cytokine network in inflammatory autoimmune diseases", J Immunol Res, 2015, pp.832127~ (2015)
7. Yoshida H, "The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene", Nature, 345, pp.442~444 (1990)[DOI]
8. Wiktor-Jedrzejczak W, "Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op", op) mouse, 1990, pp.87, 4828~4832
9. Takahashi N, "Role of colony-stimulating factors in osteoclast development", J Bone Miner Res, 6, pp.977~985 (1991)
10. Yu J, "Interaction of tumor necrosis factor receptor-associated factor 6 (TRAF6) and Vav3 in the receptor activator of nuclear factor <TEX>${\kappa}B$<", TEX> (RANK) signaling complex enhances osteoclastogenesis, 2016, pp.291, 20643~20660
11. Kim N, "A novel member of the leukocyte receptor complex regulates osteoclast differentiation", J Exp Med, 195, pp.201~209 (2002)[DOI]
12. Lee SH, "v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation", Nat Med, 12, pp.1403~1409 (2006)[DOI]
13. Rho J, "Gene expression profiling of osteoclast differentiation by combined suppression subtractive hybridization (SSH) and cDNA microarray analysis", DNA Cell Biol, 21, pp.541~549 (2002)[DOI]
14. Shin B, "Secretion of a truncated osteopetrosis-associated transmembrane protein 1 (OSTM1) mutant inhibits osteoclastogenesis through down-regulation of the B lymphocyte-induced maturation protein 1 (BLIMP1)-nuclear factor of activated T cells c1 (NFATc1) axis", J Biol Chem, 289, pp.35868~35881 (2014)[DOI]
15. Barrow AD, "OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice", J Clin Invest, 121, pp.3505~3516 (2011)[DOI]
16. Koga T, "Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis", Nature, 428, pp.758~763 (2004)[DOI]
17. Walsh MC, "Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond", Front Immunol, 5, pp.511~ (2014)
18. Azuma Y, "Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts", J Biol Chem, 275, pp.4858~4864 (2000)[DOI]
19. Komine M, "Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture", Bone, 28, pp.474~483 (2001)[DOI]
20. Kanazawa K, "TRAF5 functions in both RANKL- and TNFalpha-induced osteoclastogenesis", J Bone Miner Res, 18, pp.443~450 (2003)[DOI]
21. Kanazawa K, "TRAF2 is essential for TNF-alpha-induced osteoclastogenesis", J Bone Miner Res, 20, pp.840~847 (2005)
22. Park ES, "Tumor necrosis factor (TNF) receptor-associated factor (TRAF)-interacting protein (TRIP) negatively regulates the TRAF2 ubiquitin-dependent pathway by suppressing the TRAF2-sphingosine 1-phosphate (S1P) interaction", J Biol Chem, 290, pp.9660~9673 (2015)[DOI]
23. Zhang YH, "Tumor necrosis factor-<TEX>${\alpha}$<", TEX> (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways, 2001, pp.276, 563~568
24. Yao Z, "RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors", J Biol Chem, 292, pp.10169~10179 (2017)[DOI]
25. Kitaura H, "Immunological reaction in TNF-<TEX>${\alpha}$<", TEX>-mediated osteoclast formation and bone resorption in vitro and in vivo, 2013, pp.2013, 181849~
26. Kitaura H, "M-CSF mediates TNF-induced inflammatory osteolysis", J Clin Invest, 115, pp.3418~3427 (2005)[DOI]
27. Weitzmann MN, "Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines", Blood, 96, pp.1873~1878 (2000)
28. Hwang SJ, "Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis", Arthritis Res Ther, 14, pp.R14~ (2012)[DOI]
29. Corrado A, "Bone effects of biologic drugs in rheumatoid arthritis", Clin Dev Immunol, 2013, pp.945945~ (2013)
30. Ruscitti P, "The role of IL-<TEX>$1{\beta}$<", TEX> in the bone loss during rheumatic diseases, 2015, pp.2015, 782382~
31. Wei S, "IL-1 mediates TNF-induced osteoclastogenesis", J Clin Invest, 115, pp.282~290 (2005)[DOI]
32. Jules J, "Molecular basis of requirement of receptor activator of nuclear factor <TEX>${\kappa}B$<", TEX> signaling for interleukin 1-mediated osteoclastogenesis, 2012, pp.287, 15728~15738
33. Kim JH, "The mechanism of osteoclast differentiation induced by IL-1", J Immunol, 183, pp.1862~1870 (2009)[DOI]
34. Dinarello CA, "Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases", Nat Rev Drug Discov, 11, pp.633~652 (2012)[DOI]
35. Stefan Rose-John, "Interleukin-6 Family Cytokines", Cold Spring Harbor Perspectives in Biology, 10(2), pp.a028415~ (2018), Cold Spring Harbor Laboratory[DOI]
36. Yoshitake F, "Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways", J Biol Chem, 283, pp.11535~11540 (2008)[DOI]
37. Axmann R, "Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo", Arthritis Rheum, 60, pp.2747~2756 (2009)[DOI]
38. Blanchard F, "The dual role of IL-6-type cytokines on bone remodeling and bone tumors", Cytokine Growth Factor Rev, 20, pp.19~28 (2009)[DOI]
39. Kudo O, "Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism", Bone, 32, pp.1~7 (2003)[DOI]
40. Feng W, "Combination of IL-6 and sIL-6R differentially regulate varying levels of RANKL-induced osteoclastogenesis through <TEX>$NF-{\kappa}B$<", TEX>, ERK and JNK signaling pathways, 2017, pp.7, 41411~
41. Aguila HL, "Osteoblast-specific overexpression of human interleukin-7 rescues the bone mass phenotype of interleukin-7-deficient female mice", J Bone Miner Res, 27, pp.1030~1042 (2012)[DOI]
42. Toraldo G, "IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells", Proc Natl Acad Sci U S A, 100, pp.125~130 (2003)[DOI]
43. 유지연, "Generation of an osteoblast-based artificial niche that supports in vitro B lymphopoiesis", Experimental and Molecular Medicine, 49, pp.1~12 (2017), 생화학분자생물학회
44. Roato I, "IL-7 up-regulates TNF-<TEX>${\alpha}$<", TEX>-dependent osteoclastogenesis in patients affected by solid tumor, 2006, pp.1, e124~
45. Kim JH, "Interleukin-7 induces osteoclast formation via STAT5, independent of receptor activator of NF-kappaB ligand", Front Immunol, 8, pp.1376~ (2017)[DOI]
46. Lee SK, "Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis", Endocrinology, 144, pp.3524~3531 (2003)[DOI]
47. Bendre MS, "Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease", Bone, 33, pp.28~37 (2003)[DOI]
48. Kopesky P, "Autocrine signaling is a key regulatory element during osteoclastogenesis", Biol Open, 3, pp.767~776 (2014)[DOI]
49. Liu Y, "AB0078 Role of IL-8 and its receptor in anti-citrullinated protein antibody mediated osteoclastogenesis in RA", Ann Rheum Dis, 75, pp.923~ (2016)
50. Girasole G, "Interleukin-11: a new cytokine critical for osteoclast development", J Clin Invest, 93, pp.1516~1524 (1994)[DOI]
51. McCoy EM, "IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells", BMC Cancer, 13, pp.16~ (2013)[DOI]
52. Morgan H, "Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte", macrophage colony-stimulating factor, 2004, pp.109, 653~660
53. Ogata Y, "A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2", J Immunol, 162, pp.2754~2760 (1999)
54. Okabe I, "IL-15 and RANKL play a synergistically important role in osteoclastogenesis", J Cell Biochem, 118, pp.739~747 (2017)[DOI]
55. Lubberts E, "IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of <TEX>$NF-{\kappa}B$<", TEX> ligand, J Immunol, pp.2003, 170[DOI]
56. Lubberts E, "The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models", Arthritis Res Ther, 7, pp.29~37 (2005)[DOI]
57. Hwang SY, "IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase", Akt-dependent pathways, 2004, pp.6, 120~128
58. Jovanovic DV, "IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages", J Immunol, 160, pp.3513~3521 (1998)
59. Yago T, "IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17", J Cell Biochem, 108, pp.947~955 (2009)[DOI]
60. Moon YM, "IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis", Arthritis Res Ther, 14, pp.R246~ (2012)[DOI]
61. Kellner H, "Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential", Ther Adv Musculoskelet Dis, 5, pp.141~152 (2013)[DOI]
62. Balani D, "Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro", Arthritis Rheum, 65, pp.436~446 (2013)[DOI]
63. Chen L, "IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells", Eur J Immunol, 38, pp.2845~2854 (2008)[DOI]
64. Kang YK, "IL-23 promotes osteoclastogenesis in osteoblast-osteoclast co-culture system", Genet Mol Res, 13, pp.4673~4679 (2014)[DOI]
65. Iwakura Y, "The IL-23", IL-17 axis in inflammation, 2006, pp.116, 1218~1222
66. Chihara T, "IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation", Cell Death Differ, 17, pp.1917~1927 (2010)[DOI]
67. Chen Z, "The critical role of IL-34 in osteoclastogenesis", PLoS One, 6, pp.e18689~ (2011)[DOI]
68. Cheng X, "AG490 suppresses interleukin-34-mediated osteoclastogenesis in mice bone marrow macrophages", Cell Biol Int, 41, pp.659~668 (2017)[DOI]
69. Shi Y, "Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know", Cell Res, 16, pp.126~133 (2006)[DOI]
70. Lee MS, "GM-CSF regulates fusion of mononuclear osteoclasts into bone-resorbing osteoclasts by activating the Ras", ERK pathway, 2009, pp.183, 3390~3399
71. Ruef N, "Granulocyte-macrophage colony-stimulating factor-dependent CD11c-positive cells differentiate into active osteoclasts", Bone, 97, pp.267~277 (2017)[DOI]
72. Atanga E, "<TEX>$TNF{\alpha}$<", TEX> inhibits the development of osteoclasts through osteoblast-derived GM-CSF, 2011, pp.49, 1090~1100
73. Mackay CR, "Chemokines: immunology's high impact factors", Nat Immunol, 2, pp.95~101 (2001)[DOI]
74. Seoung-Hoon Lee, "Osteoimmunology: cytokines and the skeletal system", BMB reports, 41(7), pp.495~510 (2008), 한국생화학분자생물학회
75. Kuan WP, "CXCL 9 and CXCL 10 as Sensitive markers of disease activity in patients with rheumatoid arthritis", J Rheumatol, 37, pp.257~264 (2010)[DOI]
76. Pathak JL, "CXCL8 and CCL20 enhance osteoclastogenesis via modulation of cytokine production by human primary osteoblasts", PLoS One, 10, pp.e0131041~ (2015)[DOI]
77. Kwak HB, "Reciprocal cross-talk between RANKL and interferon-gamma-inducible protein 10 is responsible for bone-erosive experimental arthritis", Arthritis Rheum, 58, pp.1332~1342 (2008)[DOI]
78. Ha J, "CXC chemokine ligand 2 induced by receptor activator of NF-kappa B ligand enhances osteoclastogenesis", J Immunol, 184, pp.4717~4724 (2010)[DOI]
79. Koizumi K, "Role of CX3CL1", fractalkine in osteoclast differentiation and bone resorption, 2009, pp.183, 7825~7831
80. Xuan W, "Osteoclast differentiation gene expression profiling reveals chemokine CCL4 mediates RANKL-induced osteoclast migration and invasion via PI3K pathway", Cell Biochem Funct, 35, pp.171~177 (2017)[DOI]
81. Yu X, "Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration", J Bone Miner Res, 18, pp.1404~1418 (2003)[DOI]
82. Yu X, "CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts", J Bone Miner Res, 19, pp.2065~2077 (2004)[DOI]
83. Xiong Q, "The roles of interferons in osteoclasts and osteoclastogenesis", Joint Bone Spine, 83, pp.276~281 (2016)[DOI]
84. Avnet S, "Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis", Int J Oncol, 30, pp.469~476 (2007)
85. Lee Y, "The ubiquitin-mediated degradation of Jak1 modulates osteoclastogenesis by limiting interferon-beta-induced inhibitory signaling", Blood, 111, pp.885~893 (2008)[DOI]
86. Zheng H, "RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappaB that restrains osteoclastogenesis and bone resorption", J Biol Chem, 281, pp.15809~15820 (2006)[DOI]
87. Takayanagi H, "Interplay between interferon and other cytokine systems in bone metabolism", Immunol Rev, 208, pp.181~193 (2005)[DOI]
88. Hayashida C, "Osteocytes produce interferon-<TEX>${\beta}$<", TEX> as a negative regulator of osteoclastogenesis, 2014, pp.289, 11545~11555
89. Ha H, "Stimulation by TLR5 modulates osteoclast differentiation through STAT1", IFN-beta, 2008, pp.180, 1382~1389
90. Henry T, "Type I interferon signaling is required for activation of the inflammasome during Francisella infection", J Exp Med, 204, pp.987~994 (2007)[DOI]
91. Kopitar-Jerala N, "The role of interferons in inflammation and inflammasome activation", Front Immunol, 8, pp.873~ (2017)[DOI]
92. Makris S, "Type I interferons as regulators of lung inflammation", Front Immunol, 8, pp.259~ (2017)
93. Thomas KE, "Contribution of interferon-beta to the murine macrophage response to the toll-like receptor 4 agonist, lipopolysaccharide", J Biol Chem, 281, pp.31119~31130 (2006)[DOI]
94. Takayanagi H, "T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-<TEX>${\gamma}$<", TEX>, 2000, pp.408, 600~605
95. Kohara H, "IFN-<TEX>${\gamma}$<", TEX> directly inhibits TNF-<TEX>${\alpha}$<, Fas ligand interactions, pp.Immunol Lett, 2011[DOI]
96. Ji JD, "Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors", J Immunol, 183, pp.7223~7233 (2009)[DOI]
97. Baker PJ, "CD4(+) T cells and the proinflammatory cytokines gamma interferon and interleukin-6 contribute to alveolar bone loss in mice", Infect Immun, 67, pp.2804~2809 (1999)
98. Gao Y, "IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation", J Clin Invest, 117, pp.122~132 (2007)[DOI]
99. 김정우, "Effect of interferon-γ on the fusion of mononuclear osteoclasts into bone-resorbing osteoclasts", BMB Reports, 45(5), pp.281~286 (2012), 생화학분자생물학회[DOI]
100. Gupta N, "IL-3 inhibits human osteoclastogenesis and bone resorption through downregulation of c-Fms and diverts the cells to dendritic cell lineage", J Immunol, 185, pp.2261~2272 (2010)[DOI]
101. Lee J, "STAT5 is a key transcription factor for IL-3-mediated inhibition of RANKL-induced osteoclastogenesis", Sci Rep, 6, pp.30977~ (2016)[DOI]
102. Yogesha SD, "Interleukin-3 and granulocyte-macrophage colony-stimulating factor inhibits tumor necrosis factor (TNF)-<TEX>${\alpha}$<", TEX>-induced osteoclast differentiation by down-regulation of expression of TNF receptors 1 and 2, 2005, pp.280, 11759~11769
103. Wei S, "Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling", J Biol Chem, 277, pp.6622~6630 (2002)[DOI]
104. Cheng J, "Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: a novel mechanism mediating its blockade of osteoclastogenesis", J Cell Biochem, 112, pp.3385~3392 (2011)[DOI]
105. te Velde AA, "Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes", Blood, 76, pp.1392~1397 (1990)
106. Stein NC, "Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway", J Bone Miner Res, 23, pp.750~758 (2008)[DOI]
107. Onoe Y, "IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts", J Immunol, 156, pp.758~764 (1996)
108. Evans KE, "Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus", BMC Cell Biol, 8, pp.4~ (2007)[DOI]
109. Liu D, "Effect of interleukin-10 on gene expression of osteoclastogenic regulatory molecules in the rat dental follicle", Eur J Oral Sci, 114, pp.42~49 (2006)[DOI]
110. Houri-Haddad Y, "IL-10 gene transfer attenuates P. gingivalis-induced inflammation", J Dent Res, 86, pp.560~564 (2007)[DOI]
111. Kitaura H, "IL-12- and IL-18-mediated, nitric oxide-induced apoptosis in TNF-<TEX>${\alpha}$<", TEX>-mediated osteoclastogenesis of bone marrow cells, 2011, pp.89, 65~73
112. Nagata N, "Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population", Bone, 33, pp.721~732 (2003)[DOI]
113. Kitaura H, "IL-18 induces apoptosis of adherent bone marrow cells in TNF-<TEX>${\alpha}$<", TEX> mediated osteoclast formation in synergy with IL-12, 2006, pp.107, 22~31
114. Morita Y, "IL-18 inhibits TNF-alpha-induced osteoclastogenesis possibly via a T cell-independent mechanism in synergy with IL-12 in vivo", Calcif Tissue Int, 86, pp.242~248 (2010)[DOI]
115. Dai SM, "Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha", Ann Rheum Dis, 63, pp.1379~1386 (2004)[DOI]
116. Horwood NJ, "IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro", J Immunol, 166, pp.4915~4921 (2001)[DOI]
117. Furukawa M, "IL-27 abrogates receptor activator of NF-kappa B ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos", J Immunol, 183, pp.2397~2406 (2009)[DOI]
118. Kamiya S, "IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3", Immunol Lett, 138, pp.47~53 (2011)[DOI]
119. Zolochevska O, "Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro", J Cell Physiol, 228, pp.1127~1136 (2013)[DOI]
120. Kalliolias GD, "Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling", Arthritis Rheum, 62, pp.402~413 (2010)
121. Shukla P, "Interleukin 27 (IL-27) alleviates bone loss in estrogen-deficient conditions by induction of early growth response-2 gene", J Biol Chem, 292, pp.4686~4699 (2017)[DOI]
122. Kiyomiya H, "IL-33 inhibits RANKL-induced osteoclast formation through the regulation of Blimp-1 and IRF-8 expression", Biochem Biophys Res Commun, 460, pp.320~326 (2015)[DOI]
123. Lima IL, "Osteoprotective effects of IL-33", ST2 link to osteoclast apoptosis, 2015, pp.185, 3338~3348
124. Zaiss MM, "IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss", J Immunol, 186, pp.6097~6105 (2011)[DOI]
125. Mun SH, "Macrophage migration inhibitory factor down-regulates the RANKL-RANK signaling pathway by activating Lyn tyrosine kinase in mouse models", Arthritis Rheumatol, 66, pp.2482~2493 (2014)[DOI]
126. Mun SH, "Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass", J Bone Miner Res, 28, pp.948~959 (2013)[DOI]
127. Gu R, "Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis", Cytokine, 72, pp.135~145 (2015)[DOI]

관련 논문AI추천